Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy

Hypertension Research

Volumn 31, Issue 4, 2008, Pages 615-622

  Hinoi, Toshihide ^a   Tomohiro, Yasuyuki ^a   Kajiwara, Shinji ^a   Matsuo, Syusuke ^a   Fujimoto, Yukihiro ^a   Yamamoto, Shu ^a   Shichijo, Takeshi ^a   Ono, Tetuya ^a  

^a Kure Kyoshi Hospital   (Japan)

Author keywords

Angiotensin receptor blocker; Coronary circulation; Doppler echocardiography; Hypertension; Insulin resistance

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; GLUCOSE; INSULIN; LIPID; NIFEDIPINE; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOPPLER ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; MICROCIRCULATION; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; CORONARY CIRCULATION; ECHOCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; LIPIDS; MALE; MICROCIRCULATION; MIDDLE AGED;

EID: 44649187814     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.615     Document Type: Article

References (31)

1. Hozumi T, Yoshida K, Akasaka T, et al: Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998; 97: 1557-1562.
2. Pichard AD, Frolin R, Smith H, Ambrose J, Meller J: Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type: evidence for an impaired coronary vascular reserve. Am J Cardiol 1981; 47: 547-554.
3. Palombo C, Kozakova M, Magagna A, et al: Early impairment of coronary flow reserve and increase in minimum coronary resistance in borderline hypertensive patients. J Hypertens 2000; 18: 453-459.
4. Nitenberg A, Valensi P, Sachs R, Dalim M, Aptecar E, Attali JR: Impairment of coronary vascular reserve and Ach-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal ventricular systolic function. Diabetes 1993; 32: 1017-1023.
5. Nahser PJ Jr, Brown RE, Oskarsson H, Winnifold MD, Rossen JD: Maximal coronary flow reserve and metabolic coronary vasodilatation in patients with diabetes mellitus. Circulation 1995; 91: 635-640.
6. Morisita R, Higaki J, Miyazaki M, Ogihara T: Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. Hypertension 1992; 19 (Suppl 2): S62-S67.
7. Frohlich ED, Asstein C, Chobanian AV, et al: The heart in hypertension. N Engl J Med 1992; 327: 998-1008.
8. Froulich ED: Risk mechanisms in hypertensive heart disease. Hypertension 1999; 34: 782-789.
9. Kitakaze M, Asanuma H, Funaya H, et al: Angiotensin-converting enzyme inhibitor and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium. J Am Coll Cardiol 2002; 40: 162-166.
10. Motz W, Strauer BE: Improvement of coronary reserve after long-term therapy with enalapril. Hypertension 1996; 27: 1031-1038.
11. Schwartzkopff B, Brehm M, Mundhenke M, Stauer BE: Repair of coronary arteries after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220-225.
12. Akinboboye OO, Chou RI, Steven RB: Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists. A comparison of lisinoppril and losartan. J Am Coll Cardiol 2002; 40: 703-709.
13. Buns NH, Boucher M, Hermansen F, Sander M, Nielsen TT, Mulvan MJ: Influence of nitric oxide synthase and adrenegic inhibition of adenosine-induced myocardial hyperemia. Circulation 2001; 104: 2305-2310.
14. Smits P, Williams SB, Hermanson F, Banitt P, Rongen GA, Creager MA: Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995; 92: 2135-2141.
15. Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE: Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16: 123-128.
16. Prasad A, Tupas-Habis T, Schenke WH, et al: Acute and chronic angiotensin-1 receptor antagonism reserves endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-2354.
17. Kanemitsu Y, Tsuchiya K, Ohnishi H, et al: Effect of Angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamic in N-nitro-L-arginine methyl ester - treated rats. Hypertens Res 2006; 29: 369-374.
18. Morimoto S, Yano Y, Maki K, Sawada K: Renal and vascular protective effect of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567-572.
19. Nakamura T, Fujii S, Hoshino J, et al: Selective angiotensin receptor antagonism with valsaltan decrease arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28: 937-943.
20. Takami T, Shigemori M: Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26: 609-614.
21. Uchida H, Nakamura Y, Kaihara M, et al: Practical efficacy of termisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545-550.
22. Batenburg WW, Garrelds IM, Bernascom CC, et al: Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004; 109: 2296-2301.
23. Prior JO, Quinoneus MJ, Hernandez-Pampaloni M, et al: Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005; 111: 2291-2298.
24. Yokoyama I, Olitake T, Momomura SI, et al: Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes 1998; 7: 119-124.
25. Julius S, Kjeldsen SE, Weber M, et al: Outcome in hypetensive patients at high cardiovascular risk treated with regiments based on valsartan or amrodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2031.
26. Yamaguchi K, Ura N, Murakami N, et al: Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-α and cyclic AMP in skeletal muscle. Hypertens Res 2005; 28: 773-778.
27. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ modulating activity. Hypertension 2004; 43: 1-10.
28. Miura Y, Yamamoto N, Tsunekawa S, et al: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care 2005; 28: 757-758.
29. Navalkar S, Parthasarathy S, Santanam N, Khan BV: Irbesartan, an angiotensin type 1 receptor inhibitor, regulate markers of inflammation in patients in with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-444.
30. Dohi Y, Ohashi M. Sugiyama M, Takase H, Sato K, Ueda R: Candesartan reduces oxide stress and inflammation in patients with essential hypertension. Hypertens Res 2003; 26: 691-697.
31. Kadowaki D, Anraku M, Tasaki Y, et al: Effect of olmesartan on oxidative stress in hemodialysis patients. Hypertens Res 2007; 30: 395-402.